This therapeutic approach uses antisense oligonucleotides (ASOs) and RNA interference (RNAi) to selectively reduce expression of mutant huntingtin (mHTT) protein in patients with Huntington's disease (HD). By targeting the root cause of the disease—toxic gain-of-function from mutant HTT—this approach represents the most advanced disease-modifying strategy for HD currently in clinical development.
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 7 | Established approach; ASO technology mature; allele selectivity still evolving |
| Mechanistic Rationale | 9 | Direct targeting of genetic root cause; strong preclinical and clinical data |
| Root-Cause Coverage | 10 | Addresses toxic mHTT directly; disease-modifying potential |
| Delivery Feasibility | 7 | Intrathecal delivery established; AAV-RNAi promising for longer effect |
| Safety Plausibility | 7 | ASOs well-tolerated; wild-type HTT lowering a theoretical concern |
| Combinability | 8 | Can combine with symptomatic treatments, neuroprotective agents |
| Biomarker Availability | 8 | CSF mHTT measurable; NfL for progression; MRI for brain atrophy |
| De-risking Path | 8 | Clear regulatory path; multiple trials completed/ongoing |
| Multi-disease Potential | 5 | HD-specific |
| Patient Impact | 9 | High unmet need; fatal disease with no disease-modifying therapies |
Total Score: 78/100
| Disease | Coverage | Rationale |
|---|---|---|
| Huntington's Disease | 10 | Primary indication; directly targets genetic cause |
| Aging | 3 | Wild-type HTT function relevant |
Tabrizi SJ, et al. Targeting Huntingtin for Huntington's disease therapy. Nat Rev Neurol. 2019. ↩︎
Landles C, et al. The relationship between mutant huntingtin and neurodegeneration. Nat Rev Neurosci. 2020. ↩︎
Leavitt BR, et al. HTT gene silencing for Huntington disease. Sci Transl Med. 2010. ↩︎
Kordasiewicz HB, et al. HTT suppression with ASOs in Huntington disease. Neuron. 2012. ↩︎
McGowan J, et al. Antisense oligonucleotides for HTT lowering. Ann Neurol. 2018. ↩︎